| Home Options Home Health | |
| 711 Main St Sw, Ronan, Montana 59864 | |
| (406) 676-7300 | |
| Not Available |
| Name | Home Options Home Health |
|---|---|
| Location | 711 Main St Sw, Ronan, Montana |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 277019 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 59821, 59824, 59855, 59860, 59863, 59864, 59865, 59901, 59910, 59914, 59915, 59929 |
| NPI Number | 1205059649 |
| Organization Name | KALISPELL REGIONAL MEDICAL CENTER |
| Doing Business As | LAKE COUNTY HOME OPTIONS PRIVATE CARE |
| Address | 711 Main St Sw, Ronan, MT 59864 |
| Phone Number | 406-751-4200 |
News Archive
Scientists at Columbia University Mailman School of Public Health developed a method using a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES (megestrol acetate oral suspension) 625mg/5ml after the United States District Court for the District of Maryland reinstated its finding that United States Patent No. 7,101,576 (the '576 Patent) is invalid.
Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
› Verified 7 days ago
| NPI Number | 1558435271 |
| Organization Name | KALISPELL REGIONAL MEDICAL CENTER, INC |
| Doing Business As | LAKE COUNTY HOME OPTIONS HOME HEALTH |
| Address | 711 Main St Sw, Ronan, MT 59864 |
| Phone Number | 406-676-7300 |
News Archive
Scientists at Columbia University Mailman School of Public Health developed a method using a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES (megestrol acetate oral suspension) 625mg/5ml after the United States District Court for the District of Maryland reinstated its finding that United States Patent No. 7,101,576 (the '576 Patent) is invalid.
Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
› Verified 7 days ago
| Quality Rating: | Not Available* |
| * The number of patient episodes for this measure is too small to report. | |
News Archive
Scientists at Columbia University Mailman School of Public Health developed a method using a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES (megestrol acetate oral suspension) 625mg/5ml after the United States District Court for the District of Maryland reinstated its finding that United States Patent No. 7,101,576 (the '576 Patent) is invalid.
Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
› Verified 7 days ago
News Archive
Scientists at Columbia University Mailman School of Public Health developed a method using a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES (megestrol acetate oral suspension) 625mg/5ml after the United States District Court for the District of Maryland reinstated its finding that United States Patent No. 7,101,576 (the '576 Patent) is invalid.
Jefferson Hospital for Neuroscience (JHN) is launching the Jefferson Neuroscience Network (JNN) to promote collaboration among area hospitals to advance neuroscience care throughout the region. Chestnut Hill Hospital is the first hospital to join JNN. Through this collaboration, Jefferson and Chestnut Hill will provide the most sophisticated care and expertise available to patients with time-sensitive neurovascular diseases.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.
› Verified 7 days ago
Home Options Home Health Location: 711 Main St Sw, Ronan, Montana 59864 Ratings: NA Phone: (406) 676-7300 |